{"transactions":[{"id":737450,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T01:03:05.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026."}],"balance_after":30000,"derivative":{"exercise_price":26.89,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-26-020715","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000143774926020715/rdgdoc.xml","form_type":"4"}},{"id":749212,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-06-04T20:40:51.000Z","date":"2026-06-04","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":14.43,"value":360750.0,"ownership":{"direct":true},"balance_after":3123603,"source":{"system":"sec-edgar","filing":"0001569769-26-000004","document":"wk-form4_1780605646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000156976926000004/wk-form4_1780605646.xml","form_type":"4"}},{"id":749211,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2026-06-04T20:40:51.000Z","date":"2026-06-04","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":14.46,"value":361500.0,"ownership":{"direct":true},"balance_after":3098603,"source":{"system":"sec-edgar","filing":"0001569769-26-000004","document":"wk-form4_1780605646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000156976926000004/wk-form4_1780605646.xml","form_type":"4"}},{"id":1014140,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2025-10-23T20:10:15.000Z","date":"2025-10-21","kind":"grant","planned":false,"acquired":true,"shares":53361,"price":18.74,"value":999985.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025."}],"balance_after":3073603,"source":{"system":"sec-edgar","filing":"0001569769-25-000002","document":"wk-form4_1761250212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000156976925000002/wk-form4_1761250212.xml","form_type":"4"}},{"id":1061287,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-08-20T01:13:40.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025."}],"balance_after":30000,"derivative":{"exercise_price":16.16,"expiration_date":"2035-08-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-25-027392","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000143774925027392/rdgdoc.xml","form_type":"4"}},{"id":1162276,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-01T22:13:55.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":11200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025."}],"balance_after":11200000,"derivative":{"exercise_price":1.68,"expiration_date":"2033-10-13","underlying":"Common Stock","underlying_shares":11200000},"source":{"system":"sec-edgar","filing":"0001599298-25-000095","document":"wk-form4_1746137627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000159929825000095/wk-form4_1746137627.xml","form_type":"4"}},{"id":1407426,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Common Stock","published_at":"2024-09-13T21:29:01.000Z","date":"2024-09-11","kind":"grant","planned":false,"acquired":true,"shares":44052,"price":22.7,"value":999980.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person at a purchase price of $22.70 per share. The transaction closed on September 13, 2024."}],"balance_after":3020242,"source":{"system":"sec-edgar","filing":"0001599298-24-000136","document":"wk-form4_1726262933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000159929824000136/wk-form4_1726262933.xml","form_type":"4"}},{"id":1424019,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Performance Stock Option (right to buy)","published_at":"2024-08-23T20:44:41.000Z","date":"2024-08-23","kind":"grant","planned":false,"acquired":true,"shares":2800000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 11,200,000 shares underlying options which were granted on October 13, 2023 that remain subject to the satisfaction of performance conditions."}],"balance_after":2800000,"derivative":{"exercise_price":1.68,"expiration_date":"2033-10-13","underlying":"Common Stock","underlying_shares":2800000},"source":{"system":"sec-edgar","filing":"0001599298-24-000125","document":"wk-form4_1724445873.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000159929824000125/wk-form4_1724445873.xml","form_type":"4"}},{"id":1434506,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-08-13T22:53:17.000Z","date":"2024-08-09","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option will vest on the date of the Issuer's next annual meeting of stockholders and the remaining shares will vest on a monthly basis over three years thereafter, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":15.65,"expiration_date":"2034-08-09","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001437749-24-026500","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000143774924026500/rdgdoc.xml","form_type":"4"}},{"id":1470382,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T23:35:43.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 6, 2024."}],"balance_after":20000,"derivative":{"exercise_price":14.55,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-24-021127","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000143774924021127/rdgdoc.xml","form_type":"4"}},{"id":1547578,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T21:52:23.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":1100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 2, 2024. The shares underlying the option shall vest in four equal annual installments."}],"balance_after":1100000,"derivative":{"exercise_price":3.85,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0001599298-24-000060","document":"wk-form4_1712267527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000159929824000060/wk-form4_1712267527.xml","form_type":"4"}},{"id":1759678,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-16T20:06:32.000Z","date":"2023-10-13","kind":"grant","planned":false,"acquired":true,"shares":14000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 14,000,000 options which were granted on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets."}],"balance_after":14000000,"derivative":{"exercise_price":1.68,"expiration_date":"2033-10-13","underlying":"Common Stock","underlying_shares":14000000},"source":{"system":"sec-edgar","filing":"0001569769-23-000007","document":"wk-form4_1697486782.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000156976923000007/wk-form4_1697486782.xml","form_type":"4"}},{"id":1759677,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-10-16T20:06:32.000Z","date":"2023-10-13","kind":"purchase","planned":false,"acquired":true,"shares":2976190,"price":1.68,"value":4999999.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68."}],"balance_after":2976190,"source":{"system":"sec-edgar","filing":"0001569769-23-000007","document":"wk-form4_1697486782.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000156976923000007/wk-form4_1697486782.xml","form_type":"4"}},{"id":1773152,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":207.2,"expiration_date":"2030-01-02","underlying":"Class B common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773151,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":104.79,"expiration_date":"2029-08-28","underlying":"Class B common stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773150,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":175000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":72.7,"expiration_date":"2029-08-28","underlying":"Class B common stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773149,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":36.71,"expiration_date":"2033-01-03","underlying":"Class A common stock","underlying_shares":95475},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773148,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":34.15,"expiration_date":"2032-03-16","underlying":"Class A common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773147,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773146,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":121.29,"expiration_date":"2031-01-04","underlying":"Class A common stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1773145,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-09-26T16:30:36.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":62621,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019540/doc4.xml","form_type":"4"}},{"id":1803136,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-08-17T16:43:08.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":1755,"price":168.4135,"value":295565.6925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $168.3565 to $168.49. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":62621,"source":{"system":"sec-edgar","filing":"0001209191-23-046306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123046306/doc4.xml","form_type":"4"}},{"id":1819010,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class B common stock","published_at":"2023-08-01T16:47:52.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-044009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123044009/doc4.xml","form_type":"4"}},{"id":1819009,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class B common stock","published_at":"2023-08-01T16:47:52.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":75000,"price":72.7,"value":5452500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":75000,"derivative":{"underlying":"Class A common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-044009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123044009/doc4.xml","form_type":"4"}},{"id":1819008,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-08-01T16:47:52.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, representing a right to purchase a total of 250,000 shares, became exercisable as to 62,500 shares on August 28, 2020, with the remainder vesting in twelve equal quarterly installments thereafter, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":175000,"derivative":{"exercise_price":72.7,"expiration_date":"2029-08-28","underlying":"Class B common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-044009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123044009/doc4.xml","form_type":"4"}},{"id":1819007,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-08-01T16:47:52.000Z","date":"2023-07-28","kind":"sale","planned":true,"acquired":false,"shares":75000,"price":164.6173,"value":12346297.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $165.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":64376,"source":{"system":"sec-edgar","filing":"0001209191-23-044009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123044009/doc4.xml","form_type":"4"}},{"id":1819006,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-08-01T16:47:52.000Z","date":"2023-07-28","kind":"exercise","planned":true,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":139376,"source":{"system":"sec-edgar","filing":"0001209191-23-044009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123044009/doc4.xml","form_type":"4"}},{"id":1832128,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-07-10T16:47:32.000Z","date":"2023-07-06","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units granted with performance criteria (PSUs). On December 17, 2020, the reporting person was granted 6,000 PSUs. On July 6, 2023, based on certain performance criteria, the PSUs vested as to 1,500 shares, with the remainder vesting 1/12th on each subsequent 3 month anniversary, subject to continued service through each vesting date."}],"balance_after":64376,"source":{"system":"sec-edgar","filing":"0001209191-23-041931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123041931/doc4.xml","form_type":"4"}},{"id":1855605,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855604,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":250,"price":105.55,"value":26387.5,"ownership":{"direct":true},"balance_after":58376,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855603,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":14016,"price":105.0485,"value":1472359.776,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $104.515 to $105.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":58626,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855602,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":25530,"price":104.0892,"value":2657397.276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $103.51 to $104.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":72642,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855601,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":3643,"price":102.7251,"value":374227.5393,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $102.4807 to $102.995. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":98172,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855600,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":16163,"price":101.9847,"value":1648378.7061,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $101.48 to $102.44. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":101815,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855599,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":9157,"price":101.0537,"value":925348.7309,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $100.496 to $101.44. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":117978,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855598,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":9326,"price":99.7473,"value":930243.3198,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $99.50 to $100.4745. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":127135,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855597,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-13","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":27.32,"value":683000.0,"ownership":{"direct":true},"balance_after":136461,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1855596,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-06-14T16:35:27.000Z","date":"2023-06-12","kind":"sale","planned":false,"acquired":false,"shares":4711,"price":99.6173,"value":469297.1003,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $99.50 to $99.92 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":111461,"source":{"system":"sec-edgar","filing":"0001209191-23-037043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123037043/doc4.xml","form_type":"4"}},{"id":1864865,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-06T23:38:46.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023."}],"balance_after":20000,"derivative":{"exercise_price":5.95,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-23-016810","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000143774923016810/rdgdoc.xml","form_type":"4"}},{"id":1888569,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-05-17T16:39:43.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":625,"price":80.934,"value":50583.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":116172,"source":{"system":"sec-edgar","filing":"0001209191-23-030223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123030223/doc4.xml","form_type":"4"}},{"id":1888568,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-05-17T16:39:43.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":200,"price":85.6425,"value":17128.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.635 to $85.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":116797,"source":{"system":"sec-edgar","filing":"0001209191-23-030223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123030223/doc4.xml","form_type":"4"}},{"id":1888567,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-05-17T16:39:43.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":8867,"price":84.8648,"value":752496.1816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.595 to $85.545. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":116997,"source":{"system":"sec-edgar","filing":"0001209191-23-030223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123030223/doc4.xml","form_type":"4"}},{"id":1888566,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-05-17T16:39:43.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":12440,"price":84.3201,"value":1048942.044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $83.595 to $84.59 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":125864,"source":{"system":"sec-edgar","filing":"0001209191-23-030223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123030223/doc4.xml","form_type":"4"}},{"id":1899277,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-05-09T16:35:58.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 29, 2019, the reporting person was granted an option to purchase 50,000 shares of Class B common stock subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the option vested as to 50,000 shares."}],"balance_after":50000,"derivative":{"exercise_price":104.79,"exercise_date":"2023-05-05","expiration_date":"2029-08-28","underlying":"Class B common stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-028269","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123028269/doc4.xml","form_type":"4"}},{"id":1899276,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-05-09T16:35:58.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 29, 2019, the reporting person was granted 50,000 Restricted Stock Units subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the 50,000 RSUs vested."}],"balance_after":138304,"source":{"system":"sec-edgar","filing":"0001209191-23-028269","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123028269/doc4.xml","form_type":"4"}},{"id":1962804,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-03-08T17:01:34.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":622,"price":84.695,"value":52680.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":88304,"source":{"system":"sec-edgar","filing":"0001209191-23-017235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123017235/doc4.xml","form_type":"4"}},{"id":1968549,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-03-06T16:48:18.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":3587,"price":87.97,"value":315548.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $87.91 to $88.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":88926,"source":{"system":"sec-edgar","filing":"0001209191-23-016339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123016339/doc4.xml","form_type":"4"}},{"id":1983166,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-03-01T16:16:21.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2022, the reporting person was granted an option to purchase 75,000 shares of Class A common stock. On February 28, 2023 based on the satisfaction of certain performance criteria, the option vested as to 14,063 shares and is set to vest 1/16th of the original grant on each three month anniversary such that 100% of the options will be vested on the four-year anniversary of the date of grant, subject to continued service through each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":34.15,"expiration_date":"2032-03-16","underlying":"Class A common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-014095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123014095/doc4.xml","form_type":"4"}},{"id":2061743,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:09:46.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":5,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001569769-23-000004","document":"wf-form4_167295295731969.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000156976923000004/wf-form4_167295295731969.xml","form_type":"4"}},{"id":2066198,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-01-04T17:17:13.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":95475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date."}],"balance_after":95475,"derivative":{"exercise_price":36.71,"expiration_date":"2033-01-03","underlying":"Class A common stock","underlying_shares":95475},"source":{"system":"sec-edgar","filing":"0001209191-23-001143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123001143/doc4.xml","form_type":"4"}},{"id":2066197,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CFO and President"}}],"security":"Class A common stock","published_at":"2023-01-04T17:17:13.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":23513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date."}],"balance_after":92513,"source":{"system":"sec-edgar","filing":"0001209191-23-001143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123001143/doc4.xml","form_type":"4"}},{"id":2259506,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-24T00:53:14.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":116005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on August 19, 2022."}],"balance_after":116005,"derivative":{"exercise_price":2.14,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":116005},"source":{"system":"sec-edgar","filing":"0001104659-22-064004","document":"tm2216672-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000110465922064004/tm2216672-3_4seq1.xml","form_type":"4"}},{"id":2259505,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-24T00:53:14.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 19, 2022."}],"balance_after":20000,"derivative":{"exercise_price":2.14,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-064004","document":"tm2216672-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000110465922064004/tm2216672-3_4seq1.xml","form_type":"4"}},{"id":2442826,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T21:03:39.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":82446,"price":1.13,"value":93163.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $93,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022."}],"balance_after":107446,"derivative":{"exercise_price":2.82,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":82446},"source":{"system":"sec-edgar","filing":"0001599298-22-000006","document":"wf-form4_164141659851379.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000159929822000006/wf-form4_164141659851379.xml","form_type":"4"}},{"id":2442825,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T21:03:39.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.82,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001599298-22-000006","document":"wf-form4_164141659851379.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000159929822000006/wf-form4_164141659851379.xml","form_type":"4"}},{"id":2443094,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-05T16:07:48.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-001633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122001633/doc4.xml","form_type":"4"}},{"id":2443093,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Class A common stock","published_at":"2022-01-05T16:07:48.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":69000,"source":{"system":"sec-edgar","filing":"0001209191-22-001633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122001633/doc4.xml","form_type":"4"}},{"id":2447881,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Class A common stock","published_at":"2022-01-04T08:51:48.000Z","date":"2021-12-31","kind":"purchase","acquired":true,"shares":16000,"price":26.2228,"value":419564.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on one day at prices ranging from $25.97 to $26.46. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in this footnote."}],"balance_after":19000,"source":{"system":"sec-edgar","filing":"0001209191-22-000391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122000391/doc4.xml","form_type":"4"}},{"id":2700332,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-21T21:07:31.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":18.69,"exercise_date":"2021-06-20","expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-035010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919121035010/doc4.xml","form_type":"4"}},{"id":2838236,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-23T23:04:31.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021."}],"balance_after":252273,"derivative":{"exercise_price":7.33,"exercise_date":"2021-12-31","expiration_date":"2031-02-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000921895-21-000545","document":"form412566sin_02232021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000092189521000545/form412566sin_02232021.xml","form_type":"4"}},{"id":2914867,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-06T16:43:31.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in sixteen equal quarterly installments beginning on April 4, 2021, subject to continued service through each vesting date."}],"balance_after":24000,"derivative":{"exercise_price":121.29,"expiration_date":"2031-01-04","underlying":"Class A common stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-21-002143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919121002143/doc4.xml","form_type":"4"}},{"id":3057033,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Class A common stock","published_at":"2020-08-14T15:45:56.000Z","date":"2020-08-14","kind":"purchase","acquired":true,"shares":1000,"price":100.19,"value":100190.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-20-046765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919120046765/doc4.xml","form_type":"4"}},{"id":3057032,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO and CFO"}}],"security":"Class A common stock","published_at":"2020-08-14T15:45:56.000Z","date":"2020-08-14","kind":"purchase","acquired":true,"shares":2000,"price":100.22,"value":200440.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-20-046765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919120046765/doc4.xml","form_type":"4"}},{"id":3105836,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T17:07:19.000Z","date":"2020-06-17","kind":"sale","acquired":false,"shares":304,"price":62.74,"value":19072.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":5902,"source":{"system":"sec-edgar","filing":"0001209191-20-037654","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037654/doc4.xml","form_type":"4"}},{"id":3109530,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-16T20:54:28.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":61.31,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-037151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037151/doc4.xml","form_type":"4"}},{"id":3109529,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T20:54:28.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":1327,"price":60.12,"value":79779.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person"}],"balance_after":6206,"source":{"system":"sec-edgar","filing":"0001209191-20-037151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037151/doc4.xml","form_type":"4"}},{"id":3109528,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T20:54:28.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":2446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":7533,"source":{"system":"sec-edgar","filing":"0001209191-20-037151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037151/doc4.xml","form_type":"4"}},{"id":3142121,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-19T22:25:25.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":10.66,"exercise_date":"2020-06-18","expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-030680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919120030680/doc4.xml","form_type":"4"}},{"id":3317657,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-06T15:04:20.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in sixteen equal quarterly installments beginning on April 2, 2020, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":25000,"derivative":{"exercise_price":207.2,"expiration_date":"2030-01-02","underlying":"Class B common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-001636","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919120001636/doc4.xml","form_type":"4"}},{"id":3426566,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-08-29T16:20:56.000Z","date":"2019-08-28","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, representing a right to purchase a total of 250,000 shares, becomes exercisable as to 62,500 shares on August 28, 2020, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":250000,"derivative":{"exercise_price":72.7,"expiration_date":"2029-08-28","underlying":"Class B common stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-19-047700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919119047700/doc4.xml","form_type":"4"}},{"id":3488371,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-17T18:53:51.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":56.5,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-037506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037506/doc4.xml","form_type":"4"}},{"id":3488370,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:53:51.000Z","date":"2019-06-14","kind":"sale","acquired":false,"shares":133,"price":56.5116,"value":7516.0428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $56.64, inclusive."}],"balance_after":5087,"source":{"system":"sec-edgar","filing":"0001209191-19-037506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037506/doc4.xml","form_type":"4"}},{"id":3488369,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:53:51.000Z","date":"2019-06-14","kind":"sale","acquired":false,"shares":1084,"price":55.8172,"value":60505.8448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.47 to $56.43, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4."}],"balance_after":5220,"source":{"system":"sec-edgar","filing":"0001209191-19-037506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037506/doc4.xml","form_type":"4"}},{"id":3488368,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:53:51.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":6304,"source":{"system":"sec-edgar","filing":"0001209191-19-037506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037506/doc4.xml","form_type":"4"}},{"id":3520146,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-17T20:17:28.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":13814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":13814,"derivative":{"exercise_price":13.03,"exercise_date":"2019-09-05","expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":13814},"source":{"system":"sec-edgar","filing":"0001209191-19-030896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919119030896/doc4.xml","form_type":"4"}},{"id":3520145,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-17T20:17:28.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":13.03,"exercise_date":"2019-06-16","expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-030896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919119030896/doc4.xml","form_type":"4"}},{"id":3623455,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2019-03-01T23:10:31.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 10,000 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":20000,"derivative":{"exercise_price":85,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001735276-19-000033","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000033/edgardoc.xml","form_type":"4"}},{"id":3698793,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-09T21:15:55.000Z","date":"2019-01-07","kind":"grant","acquired":true,"shares":4066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will fully vest on the date of the Issuer's Annual Meeting to be held in 2019, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":4066,"derivative":{"exercise_price":13.22,"expiration_date":"2029-01-07","underlying":"Common Stock","underlying_shares":4066},"source":{"system":"sec-edgar","filing":"0001209191-19-003039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919119003039/doc4.xml","form_type":"4"}},{"id":3729757,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-17T16:25:14.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) beginning on the one-month anniversary of the grant date and ending on the one-year anniversary of our most recent annual meeting of stockholders, and are exercisable once vested."}],"balance_after":2500,"derivative":{"exercise_price":41.09,"expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-062940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118062940/doc4.xml","form_type":"4"}},{"id":3729756,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-17T16:25:14.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in 36 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over three years beginning on January 14, 2019, and are exercisable once vested."}],"balance_after":2500,"derivative":{"exercise_price":41.09,"expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-18-062940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118062940/doc4.xml","form_type":"4"}},{"id":3729755,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-17T16:25:14.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":1825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":1825,"source":{"system":"sec-edgar","filing":"0001209191-18-062940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118062940/doc4.xml","form_type":"4"}},{"id":3729754,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-17T16:25:14.000Z","date":"2018-12-14","kind":"grant","acquired":true,"shares":1825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in three equal installments on the dates of Arena's next three annual meetings of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":1825,"source":{"system":"sec-edgar","filing":"0001209191-18-062940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118062940/doc4.xml","form_type":"4"}},{"id":3844923,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2018-08-14T21:54:10.000Z","date":"2018-08-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 8, 2017, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee.  Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested."}],"balance_after":25000,"derivative":{"exercise_price":52.61,"exercise_date":"2018-08-13","expiration_date":"2027-05-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001735276-18-000048","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000048/edgardoc.xml","form_type":"4"}},{"id":3844922,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-14T21:54:10.000Z","date":"2018-07-10","kind":"other","acquired":true,"shares":36,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":83,"source":{"system":"sec-edgar","filing":"0001735276-18-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000048/edgardoc.xml","form_type":"4"}},{"id":3844921,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-14T21:54:10.000Z","date":"2018-04-16","kind":"other","acquired":true,"shares":28,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":47,"source":{"system":"sec-edgar","filing":"0001735276-18-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000048/edgardoc.xml","form_type":"4"}},{"id":3844920,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-14T21:54:10.000Z","date":"2018-01-17","kind":"other","acquired":true,"shares":6,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":19,"source":{"system":"sec-edgar","filing":"0001735276-18-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000048/edgardoc.xml","form_type":"4"}},{"id":3844919,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-14T21:54:10.000Z","date":"2017-10-16","kind":"other","acquired":true,"shares":11,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":13,"source":{"system":"sec-edgar","filing":"0001735276-18-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000048/edgardoc.xml","form_type":"4"}},{"id":3844918,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-08-14T21:54:10.000Z","date":"2017-07-25","kind":"other","acquired":true,"shares":2,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":2,"source":{"system":"sec-edgar","filing":"0001735276-18-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000048/edgardoc.xml","form_type":"4"}},{"id":3918214,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-24T22:38:40.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":15.27,"exercise_date":"2018-06-23","expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-033155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919118033155/doc4.xml","form_type":"4"}},{"id":4015851,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2018-03-05T22:49:47.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":8938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 8,937 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months"}],"balance_after":8938,"derivative":{"exercise_price":119.13,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":8938},"source":{"system":"sec-edgar","filing":"0001553878-18-000014","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000014/edgardoc.xml","form_type":"4"}},{"id":4171086,"issuer":{"id":1151,"kind":"organization","name":"PULSE BIOSCIENCES, INC.","symbol":"PLSE"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-11-06T21:44:36.000Z","date":"2017-11-02","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the shares subject to the option will vest on November 2, 2018, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":65000,"derivative":{"exercise_price":23.08,"exercise_date":"2018-11-02","expiration_date":"2027-11-02","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-17-059429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569769/000120919117059429/doc4.xml","form_type":"4"}},{"id":4443825,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T14:14:49.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":7937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the \"RSU Payment\").  Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the \"RSU Payment\").  Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7937},"source":{"system":"sec-edgar","filing":"0000884731-17-000049","document":"wf-form4_148727247586013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000049/wf-form4_148727247586013.xml","form_type":"4"}},{"id":4443824,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-02-16T14:14:49.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":6.47,"underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0000884731-17-000049","document":"wf-form4_148727247586013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000049/wf-form4_148727247586013.xml","form_type":"4"}},{"id":4443823,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2017-02-16T14:14:49.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":3273,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the \"Merger Agreement\"), between the Company, Takeda Pharmaceutical Company Limited (\"Takeda\") and Kiku Merger Co., Inc. (\"Purchaser\"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $24.00 in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents Shares purchased through the Company's employee stock purchase plan, including 538 Shares on February 14, 2017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000884731-17-000049","document":"wf-form4_148727247586013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000049/wf-form4_148727247586013.xml","form_type":"4"}},{"id":4465013,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":38041,"kind":"person","name":"Soni Manmeet Singh","position":1,"cik":"0001569769","reported_name":"Soni Manmeet Singh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & Treasurer"}}],"security":"Restricted Stock Units","published_at":"2017-02-07T16:58:51.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":7937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Stock Units (\"RSUs\") vest as to approximately one-third of the shares underlying the RSUs on each anniversary of the grant date; provided, however, that, subject to and effective upon the consummation of the transactions contemplated by that certain Agreement and Plan of Merger between ARIAD, Takeda Pharmaceutical Company Limited, and Kiku Merger Co., Inc., dated January 8, 2017, the RSUs shall be converted into the right to receive a cash amount equal to $24.00 for each share of common stock underlying the RSUs, payable in three annual installments on each anniversary of the grant date, subject to the terms of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"N/A"}],"balance_after":7937,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7937},"source":{"system":"sec-edgar","filing":"0000884731-17-000030","document":"wf-form4_148650471771951.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000030/wf-form4_148650471771951.xml","form_type":"4"}}]}